NBTX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

1 Analyst Rating

Wall Street analysts forecast NBTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NBTX is 24.00 USD with a low forecast of 24.00 USD and a high forecast of 24.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

24.00

Averages

24.00

High

24.00

Current: 0.000

Low

24.00

Averages

24.00

High

24.00

H.C. Wainwright

Buy

maintain

2025-11-04

Reason

H.C. Wainwright

Price Target

2025-11-04

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Nanobiotix to EUR 23 from EUR 20 and keeps a Buy rating on the shares. The firm believes the company's "non-dilutive" financing arrangement with HealthCare Royalty brings validation.

H.C. Wainwright

NULL -> Buy

upgrade

2025-09-19

Reason

H.C. Wainwright

Price Target

2025-09-19

upgrade

NULL -> Buy

Reason

H.C. Wainwright raised the firm's price target on Nanobiotix to EUR 13 from EUR 10 and keeps a Buy rating on the shares. The company announced positive results from the melanoma patient subset of cohort 3 of the ongoing Phase 1 Study 1100 evaluating JNJ-1900, the analyst tells investors in a research note.

Leerink

Jonathan Chang

Outperform

maintain

$9 -> $14

2025-09-18

Reason

Leerink

Jonathan Chang

Price Target

$9 -> $14

2025-09-18

maintain

Outperform

Reason

Leerink analyst Jonathan Chang raised the firm's price target on Nanobiotix to $14 from $9 and keeps an Outperform rating on the shares. Nanobiotix reported the first data update for NBTXR3 in anti-PD-1 resistant melanoma from its Phase I Study 1100, showing promising results that are supportive of further investigation in this indication, the analyst tells investors in a research note. Given the early nature of the data, Leerink continues to view this opportunity as upside to the firm's estimates.

Guggenheim

Michael Schmidt

Strong Buy

Maintains

$12 → $8

2025-04-04

Reason

Guggenheim

Michael Schmidt

Price Target

$12 → $8

2025-04-04

Maintains

Strong Buy

Reason

Guggenheim lowered the firm's price target on Nanobiotix to $8 from $12 and keeps a Buy rating on the shares. After the company reported FY24 earnings consistent with prior disclosures, the firm is updating its model to reflect second half results and remove assumptions for recurrent/metastatic head and neck squamous cell carcinoma.

Valuation Metrics

The current forward P/E ratio for Nanobiotix SA (NBTX.O) is 163.39, compared to its 5-year average forward P/E of -4.69. For a more detailed relative valuation and DCF analysis to assess Nanobiotix SA 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.69

Current PE

163.39

Overvalued PE

73.88

Undervalued PE

-83.27

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-6.25

Current EV/EBITDA

-34.44

Overvalued EV/EBITDA

0.98

Undervalued EV/EBITDA

-13.49

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

58.68

Current PS

14.39

Overvalued PS

143.05

Undervalued PS

-25.69

Financials

Annual

Quarterly

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 1048.78% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

NBTX News & Events

Events Timeline

No data

News

9.5

2025-12-31NASDAQ.COM

Palvella Therapeutics Stock Soars to $114.69 Following Pipeline Developments

7.5

2025-12-17Globenewswire

Nanobiotix Reports Voting Rights and Share Capital Data

9.0

2025-12-17Yahoo Finance

Shareholder Voting Rights and Company Capital Structure

People Also Watch

Frequently Asked Questions

What is Nanobiotix SA (NBTX) stock price today?

The current price of NBTX is 20.54 USD — it has increased 2.85 % in the last trading day.

What is Nanobiotix SA (NBTX)'s business?

Nanobiotix SA is a France-based nanomedicine company. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. It develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.

What is the price predicton of NBTX Stock?

What is Nanobiotix SA (NBTX)'s revenue for the last quarter?

Nanobiotix SA revenue for the last quarter amounts to NaN USD, decreased % YoY.

What is Nanobiotix SA (NBTX)'s earnings per share (EPS) for the last quarter?

Nanobiotix SA. EPS for the last quarter amounts to USD, decreased % YoY.

What changes have occurred in the market's expectations for Nanobiotix SA (NBTX)'s fundamentals?

The market is revising No Change the revenue expectations for NBTX for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -12.97%.

How many employees does Nanobiotix SA (NBTX). have?

Nanobiotix SA (NBTX) has 108 emplpoyees as of January 10 2026.

What is Nanobiotix SA (NBTX) market cap?

Today NBTX has the market capitalization of 993.70M USD.